ClinicalTrials.gg
CompletedNCT01299389Updated Jun 17, 2013Results posted

An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia

A Phase 3 interventional study of Paliperidone palmitate and Placebo in Schizophrenia, sponsored by Janssen Pharmaceutical K.K.. Completed at 57 sites in 3 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-06-17.

Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
323
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
34th of 115
323 · median 178
Started
2010
with 7 others
Phase 3
41 of 115
none open now
Registered
63rd of 115
by date
Lead sponsor
7 of 115
Janssen Pharmaceutical K.K.

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 34th largest by enrollment, is one of 8 that started in 2010, is one of 41 in phase 3, and was the 63rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of paliperidone palmitate as compared with placebo in the treatment of participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions [a false belief held in the face of strong differing evidence, especially as a symptom of psychiatric disorder] and hallucinations [imagining things], and withdrawal into the self).

Read the detailed description

This is a randomized (the study drug is assigned by chance), double-blind (neither physician nor participant knows the name of the assigned drug), placebo-controlled (an inactive substance; a pretend treatment [with no drug in it] that is compared in a clinical trial with a drug to test if the drug has a real effect), parallel-group (comparing the response in two groups of participants receiving different treatments), fixed-dose, multi-center (when more than one hospital or medical school team work on a medical research study) study of paliperidone palmitate in participants with schizophrenia. The study will consist of 3 periods: an up to 2-week pre-observation (screening) period, a double-blind period from Day 1 (baseline) to Week 13 (end of double-blind period) assessment, and a post-observation period starting after the Week 13 assessment to Week 21. For participants who discontinue the study before the last assessment in Week 13, the post-observation period will start after the discontinuation from double-blind period assessment with follow-up visits at 4, 8, and 12 weeks after the last injection. After completion of the double-blind period (Week 13), discontinuation of double-blind period treatment or withdrawal from the study, participants may receive treatment consistent with the usual standard of care. The total duration of the study will be 21 weeks, including the double-blind and post-observation periods. Participants will be randomly assigned to 1 of 2 treatment groups in a 1:1 ratio (intramuscular injections of either paliperidone palmitate or matching placebo). Injections of paliperidone palmitate or placebo will be given at Day 1 and at Weeks 1, 5, and 9 by a study drug manager and/or injector. For those participants receiving paliperidone palmitate, the Day 1 injection will be 150 milligram equivalent (mg eq.) paliperidone palmitate, followed by 100 mg eq. injections of paliperidone palmitate at Week 1, and 75 mg eq. injections of paliperidone palmitate at Weeks 5 and 9. Participants randomly assigned to placebo will receive injections matching the paliperidone palmitate injections on the same days. Efficacy will be assessed using Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression - Severity (CGI-S). Participant's safety will be monitored throughout the study.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Paliperidone palmitate
  • Schizophrenia
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants meeting Diagnostic criteria for schizophrenia according to , Fourth Edition Text Revision
  • Women had to be: (for at least 2 years), surgically sterile (had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), abstinent (as judged by the investigator; per local regulations), or if sexually active, be practicing a highly effective method of (eg, prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [eg, condoms, diaphragm, or cervical cap, with spermicidal foam, cream, or gel], male partner sterilization) as local regulations permitted, before entry, and had to agree to continue to use the same method of contraception throughout the study
  • A Positive and Negative Syndrome Scale (PANSS) total score at screening and at baseline (Day 1) of 60 to 120
  • Documented history of exposure to either a risperidone formulation or a paliperidone formulation and known to be tolerated before baseline (Day 1) (Even if the participant's experience of taking risperidone or paliperidone cannot be confirmed at the time of , the participant will be able to meet this criterion if the participant takes oral risperidone 2 mg/day or more or paliperidone ER 6 mg/day or more for at least 4 days between the day of informed consent and the day before baseline, and it is possible to confirm that there is no lack of tolerability in the participant)
  • Women of must have a negative beta human chorionic gonadotropin pregnancy test at the screening urine pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Primary active , Fourth Edition Text Revision Axis I diagnosis other than schizophrenia
  • A Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision diagnosis of active substance dependence within 3 months before screening (nicotine and caffeine are not exclusionary)
  • Relevant history or current presence of any significant or unstable cardiovascular, respiratory, neurological (including seizures or significant cerebrovascular), renal, hepatic, hematologic, endocrine, immunologic, or other systemic disease
  • History or current presence of neuroleptic malignant syndrome or tardive dyskinesia
  • Known or suspected or intolerance to risperidone, paliperidone, Intralipid, or any of their (including egg yolks, soybean oil, phospholipids, and glycerol)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
323 participants (actual)

Study arms

  • Experimental
    Paliperidone palmitate

    Drug: Paliperidone palmitate

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Paliperidone palmitate will be given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.

  • DrugPlacebo

    Matching Placebo will be given intramuscularly (Injection of a drug into a muscle) on Day 1, Day 8, Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation

    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210, higher scores indicate worsening.

    Time frame: Baseline and Week 13 or early discontinuation

Secondary outcomes

  1. Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 13 or Early Discontinuation

    The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants", higher scores indicate worsening.

    Time frame: Baseline and Week 13 or early discontinuation

  2. Participants With Response to the Treatment as Per PANSS Total Score.

    Participants with response were defined as those participants who shows 30 percent or more and 20 percent or more reduction in PANSS total score.

    Time frame: up to Week 13 or early discontinuation

  3. Change From Baseline in PANSS Marder Subscale Scores at Week 13 or Early Discontinuation

    The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). Positive symptoms subscale consists of 8 items with total score range of 8-56; negative symptoms subscale and disorganized thoughts subscale, each consists of 7 items with total score range of 7-49, uncontrolled hostility/excitement subscale and anxiety/depression subscale, each consists of 4 items with total score range of 4-28, higher score indicates greater severity.

    Time frame: Baseline and Week 13 or early discontinuation (ED)

  4. Change From Baseline in PANSS Negative Subscale Score at Week 13 or Early Discontinuation

    Negative Syndrome Scale (range 7-49): Sum of scores for items 1-7 in negative subscale: blunted effect, emotional withdrawal, poor rapport, passive apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking, higher scores indicate worsening.

    Time frame: Baseline and Week 13 or early discontinuation

  5. Change From Baseline in PANSS Positive Subscale Score at Week 13 or Early Discontinuation

    Positive Syndrome Scale (range 7-49): Sum of scores for items 1-7 in positive subscale: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility, higher scores indicate worsening.

    Time frame: Baseline and Week 13 or early discontinuation

  6. Change From Baseline in PANSS General Psychopathology Subscale Score at Week 13 or Early Discontinuation

    General Psychopathology (range 16-112): Sum of scores for somatic concern, anxiety, guilt feelings, tension, mannerisms/posturing, depression, motor retardation, uncooperativeness, unusual thought content, disoriented, poor attention, lack of judgment/insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance, higher scores indicate worsening.

    Time frame: Baseline and Week 13 or early discontinuation

07

Results

Posted Jun 17, 2013

Participant flow

Double-blind
Participant flow — Double-blind
MilestonePlacebo (Double-blind)Paliperidone Palmitate (Double-blind)Placebo (Post-observational)Paliperidone Palmitate (Post-observational)
Started16415900
Completed559500
Not completed1096400
Withdrew: Adverse event452700
Withdrew: Lack of efficacy452100
Withdrew: Lost to follow-up2100
Withdrew: Withdrawal by subject161300
Withdrew: Other1100
Withdrew: Fail to meet "study population" criteria0100
Post-observational
Participant flow — Post-observational
MilestonePlacebo (Double-blind)Paliperidone Palmitate (Double-blind)Placebo (Post-observational)Paliperidone Palmitate (Post-observational)
Started00156155
Completed00144149
Not completed00126
Withdrew: Other00126

Outcome measures

PrimaryChange From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210, higher scores indicate worsening.

Time frame:
Baseline and Week 13 or early discontinuation
Reported as:
Mean · units on a scale
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation
units on a scalePlacebo (Double-blind)Paliperidone Palmitate (Double-blind)
Baseline83.5 ± 15.1885.7 ± 14.57
Change at Week 13 or Early Discontinuation6.9 ± 19.13-3.1 ± 20.32
Statistical analysis
  • Placebo (Double-blind) vs Paliperidone Palmitate (Double-blind) · ANCOVA · p = <0.0001 · Least squares (ls) means difference: -9.7 · 95% CI -14.0 to -5.4
SecondaryChange From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 13 or Early Discontinuation

The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants", higher scores indicate worsening.

Time frame:
Baseline and Week 13 or early discontinuation
Reported as:
Median · units on a scale
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 13 or Early Discontinuation
units on a scalePlacebo (Double-blind)Paliperidone Palmitate (Double-blind)
Baseline4.0 (2 to 7)4.0 (2 to 6)
Change at Week 13 or Early Discontinuation0.0 (-3 to 3)0.0 (-3 to 3)
SecondaryParticipants With Response to the Treatment as Per PANSS Total Score.

Participants with response were defined as those participants who shows 30 percent or more and 20 percent or more reduction in PANSS total score.

Time frame:
up to Week 13 or early discontinuation
Reported as:
Number · participants
Participants With Response to the Treatment as Per PANSS Total Score.
participantsPlacebo (Double-blind)Paliperidone Palmitate (Double-blind)
Greater than or equal to 30 percent Improvement1436
Greater than or equal to 20 percent Improvement2352
SecondaryChange From Baseline in PANSS Marder Subscale Scores at Week 13 or Early Discontinuation

The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). Positive symptoms subscale consists of 8 items with total score range of 8-56; negative symptoms subscale and disorganized thoughts subscale, each consists of 7 items with total score range of 7-49, uncontrolled hostility/excitement subscale and anxiety/depression subscale, each consists of 4 items with total score range of 4-28, higher score indicates greater severity.

Time frame:
Baseline and Week 13 or early discontinuation (ED)
Reported as:
Mean · units on a scale
Change From Baseline in PANSS Marder Subscale Scores at Week 13 or Early Discontinuation
units on a scalePlacebo (Double-blind)Paliperidone Palmitate (Double-blind)
Positive symptoms: Baseline24.3 ± 5.5624.2 ± 5.66
Positive symptoms: Change at Week 13 or ED1.6 ± 6.06-1.1 ± 6.29
Negative symptoms: Baseline21.7 ± 6.2222.8 ± 6.04
Negative symptoms: Change at Week 13 or ED0.9 ± 5.82-1.4 ± 5.76
Disorganized thoughts: Baseline19.6 ± 5.1320.8 ± 4.83
Disorganized thoughts: Change at Week 13 or ED1.9 ± 5.24-0.6 ± 5.11
Uncontrolled hostility/excitement: Baseline8.3 ± 3.078.6 ± 3.42
Uncontrolled hostility: Change at Week 13 or ED1.9 ± 4.230.4 ± 4.15
Anxiety/depression: Baseline9.5 ± 3.029.4 ± 3.14
Anxiety/depression: Change at Week 13 or ED0.7 ± 3.27-0.4 ± 3.54
Statistical analysis
  • Placebo (Double-blind) vs Paliperidone Palmitate (Double-blind) · ANCOVA · p = <0.0001 · Ls mean difference: -2.7 · 95% CI -4.1 to -1.4
  • Placebo (Double-blind) vs Paliperidone Palmitate (Double-blind) · ANCOVA · p = 0.0012 · Ls mean difference: -2.0 · 95% CI -3.2 to -0.8
  • Placebo (Double-blind) vs Paliperidone Palmitate (Double-blind) · ANCOVA · p = <0.0001 · Ls mean difference: -2.2 · 95% CI -3.4 to -1.1
  • Placebo (Double-blind) vs Paliperidone Palmitate (Double-blind) · ANCOVA · p = 0.0023 · Ls mean difference: -1.4 · 95% CI -2.3 to -0.5
  • Placebo (Double-blind) vs Paliperidone Palmitate (Double-blind) · ANCOVA · p = 0.0025 · Ls mean difference: -1.1 · 95% CI -1.9 to -0.4
SecondaryChange From Baseline in PANSS Negative Subscale Score at Week 13 or Early Discontinuation

Negative Syndrome Scale (range 7-49): Sum of scores for items 1-7 in negative subscale: blunted effect, emotional withdrawal, poor rapport, passive apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking, higher scores indicate worsening.

Time frame:
Baseline and Week 13 or early discontinuation
Reported as:
Mean · units on a scale
Change From Baseline in PANSS Negative Subscale Score at Week 13 or Early Discontinuation
units on a scalePlacebo (Double-blind)Paliperidone Palmitate (Double-blind)
Baseline22.7 ± 6.1924.0 ± 5.77
Change at Week 13 or Early Discontinuation0.9 ± 5.54-1.5 ± 5.38
Statistical analysis
  • Placebo (Double-blind) vs Paliperidone Palmitate (Double-blind) · ANCOVA · p = 0.0003 · Ls mean difference: -2.1 · 95% CI -3.3 to -1.0
SecondaryChange From Baseline in PANSS Positive Subscale Score at Week 13 or Early Discontinuation

Positive Syndrome Scale (range 7-49): Sum of scores for items 1-7 in positive subscale: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility, higher scores indicate worsening.

Time frame:
Baseline and Week 13 or early discontinuation
Reported as:
Mean · units on a scale
Change From Baseline in PANSS Positive Subscale Score at Week 13 or Early Discontinuation
units on a scalePlacebo (Double-blind)Paliperidone Palmitate (Double-blind)
Baseline19.3 ± 4.9719.5 ± 5.47
Change at Week 13 or Early Discontinuation2.2 ± 5.82-0.6 ± 6.19
Statistical analysis
  • Placebo (Double-blind) vs Paliperidone Palmitate (Double-blind) · ANCOVA · p = <0.0001 · Ls mean difference: -2.8 · 95% CI -4.1 to -1.5
SecondaryChange From Baseline in PANSS General Psychopathology Subscale Score at Week 13 or Early Discontinuation

General Psychopathology (range 16-112): Sum of scores for somatic concern, anxiety, guilt feelings, tension, mannerisms/posturing, depression, motor retardation, uncooperativeness, unusual thought content, disoriented, poor attention, lack of judgment/insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance, higher scores indicate worsening.

Time frame:
Baseline and Week 13 or early discontinuation
Reported as:
Mean · units on a scale
Change From Baseline in PANSS General Psychopathology Subscale Score at Week 13 or Early Discontinuation
units on a scalePlacebo (Double-blind)Paliperidone Palmitate (Double-blind)
Baseline41.4 ± 7.9742.3 ± 7.85
Change at Week 13 or Early Discontinuation3.8 ± 10.32-1.0 ± 11.04
Statistical analysis
  • Placebo (Double-blind) vs Paliperidone Palmitate (Double-blind) · ANCOVA · p = <0.0001 · Ls mean difference: -4.6 · 95% CI -6.9 to -2.3

Adverse events

Collected over From signing of the informed consent until study completion.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Double-blind)—25/164 (15.2%)131/164 (79.9%)
Paliperidone Palmitate (Double-blind)—10/159 (6.3%)133/159 (83.6%)
Placebo (Post-observational)—4/156 (2.6%)94/156 (60.3%)
Paliperidone Palmitate (Post-0bservational)—6/155 (3.9%)79/155 (51%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPlacebo (Double-blind)Paliperidone Palmitate (Double-blind)Placebo (Post-observational)Paliperidone Palmitate (Post-0bservational)
Psychiatric symptomPsychiatric disorders13/1644/1592/1562/155
SchizophreniaPsychiatric disorders3/1644/1592/1562/155
Suicide attemptPsychiatric disorders2/1640/1590/1560/155
Hallucination, auditoryPsychiatric disorders1/1640/1590/1561/155
AkathisiaNervous system disorders0/1640/1590/1561/155
Mental status changesPsychiatric disorders0/1641/1590/1560/155
ConvulsionNervous system disorders0/1641/1590/1560/155
Ankle fractureInjury, poisoning and procedural complications0/1641/1590/1560/155
DehydrationMetabolism and nutrition disorders1/1640/1590/1560/155
HyponatraemiaMetabolism and nutrition disorders1/1640/1590/1560/155
Most frequent other events
Showing 10 of 308
Most frequent other events
EventPlacebo (Double-blind)Paliperidone Palmitate (Double-blind)Placebo (Post-observational)Paliperidone Palmitate (Post-0bservational)
Psychiatric symptomPsychiatric disorders33/16414/1594/1562/155
InsomniaPsychiatric disorders25/16427/1596/1566/155
Injection site painGeneral disorders11/16421/1591/1560/155
NasopharyngitisInfections and infestations10/16420/15913/15613/155
Extrapyramidal disorderNervous system disorders8/16416/1596/1561/155
ConstipationGastrointestinal disorders9/1649/15913/1568/155
AnxietyPsychiatric disorders13/16410/1595/1561/155
AkathisiaNervous system disorders3/1648/15911/1565/155
Upper respiratory tract infectionInfections and infestations7/1648/1594/1566/155
HeadacheNervous system disorders6/1648/1595/1564/155

Baseline characteristics

Safety analysis set included all randomly assigned participants who received at least 1 injection of double-blind study drug.

Age Continuous
Age Continuous(years)Placebo (Double-blind)Paliperidone Palmitate (Double-blind)Total
Mean44.0 ± 12.4145.7 ± 13.5544.8 ± 12.99
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (Double-blind)Paliperidone Palmitate (Double-blind)Total
Female8158139
Male83101184
08

Study locations

57 sites
  • Fujioka, Japan
  • Fujisawa, Japan
  • Fukui, Japan
  • Fukuoka, Japan
  • Hadano, Japan
  • Ichikawa, Japan
  • Itoman, Japan
  • Kanzaki, Japan
  • Kashihara, Japan
  • Kasuya, Japan
  • Kawasaki, Japan
  • Kitagunma, Japan
  • Kitakyushu, Japan
  • Kobe, Japan
  • Kodaira, Japan
  • Koshigaya, Japan
  • Kumagaya, Japan
  • Kumamoto, Japan
  • Kurayoshi, Japan
  • Kure, Japan
  • Kurume, Japan
  • Mitaka, Japan
  • Miyazaki, Japan
  • Moriguchi, Japan
  • Nanyo, Japan
  • Nishinomiya, Japan
  • Ohta, Japan
  • Okinawa, Japan
  • Oyabe, Japan
  • Sakai, Japan
  • Shibukawa, Japan
  • Takatsuki, Japan
  • Tamana, Japan
  • Tokyo, Japan
  • Toyama, Japan
  • Toyoake, Japan
  • Urasoe, Japan
  • Yatsushiro, Japan
  • Yokkaichi, Japan
  • Yokohama, Japan
  • Busan, Korea, Republic of
  • Chonju, Korea, Republic of
  • Chungcheongbuk-Do, Korea, Republic of
  • Daegu, Korea, Republic of
  • Deajun, Korea, Republic of
  • Incheon, Korea, Republic of
  • Inchun, Korea, Republic of
  • Seongnam, Korea, Republic of
  • Seoul, Korea, Republic of
  • Bali Township, Taipei County, Taiwan
  • Changhua, Taiwan
  • Hua Lian, Taiwan
  • Hualien, Taiwan
  • Kaohsiung, Taiwan
  • Tainan, Taiwan
  • Taipei, Taiwan
  • Taoyuan, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2011
First posted
Feb 18, 2011
Start
Oct 2010
Primary completionActual
May 2012
CompletionActual
May 2012
Results first posted
Jun 17, 2013
Last update
Jun 17, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01299389
Responsible party
Sponsor
First posted
Feb 18, 2011
Start date
Oct 2010
Primary completion
May 2012
Completion
May 2012
Results posted
Jun 17, 2013
Last update
Jun 17, 2013

Study contacts

Janssen Pharmaceutical K.K. Clinical Trial
study director · Janssen Pharmaceutical K.K.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion